Drug profile · INN
eravacycline dihydrochloride
XERAVA
eravacycline dihydrochloride (XERAVA) is a bacterial 70s ribosome inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — eravacycline dihydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
eravacycline dihydrochloride (XERAVA) is a bacterial 70s ribosome inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is eravacycline dihydrochloride?
eravacycline dihydrochloride (XERAVA) is a bacterial 70s ribosome inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for eravacycline dihydrochloride?
XERAVA is a marketed brand name for eravacycline dihydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eravacycline dihydrochloride?
eravacycline dihydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.